Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple scan and blood test outsmart liver cancer?

NCT ID NCT07764835

Knowledge-focused Sponsor: D'Or Institute for Research and Education Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study looks at whether a structured surveillance program using regular ultrasound and a blood test (alpha-fetoprotein) can detect liver cancer at an earlier, more treatable stage in people at high risk. About 300 adults with liver cirrhosis, chronic hepatitis B, or advanced liver fibrosis will be followed for up to 36 months. The goal is to see how often liver cancer is found, at what stage, and how quickly patients move from detection to treatment in real-world clinics.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Semiannual abdominal ultrasound (US LI-RADS) and alpha-fetoprotein (AFP) blood test
What this could lead to
If successful, this could improve early detection of liver cancer, leading to better outcomes for at-risk patients.
What could go wrong
This is an observational study, so it won't prove the surveillance program causes better outcomes. Also, the effectiveness depends on real-world adherence and may vary across centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients at increased risk for hepatocellular carcinoma, including individuals with liver cirrhosis, chronic hepatitis B, advanced fibrosis, and metabolic dysfunction-associated steatotic liver disease who are receiving routine care within the Rede D'Or healthcare network.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent. * Age 18 years or older. * Liver cirrhosis of any etiology. * Chronic hepatitis B with moderate or high risk of HCC according to PAGE-B criteria. * Non-cirrhotic chronic liver disease with increased risk for HCC, including fibrosis stage 3 or higher or metabolic dysfunction-associated steatotic liver disease (MASLD) with one or more risk factors for HCC. * Followed at hepatology clinics within the Rede D'Or health network. * Eligible for routine HCC surveillance with ultrasound and alpha-fetoprotein according to standard clinical practice. Exclusion Criteria: * Known hepatocellular carcinoma at enrollment. * Previous diagnosis of hepatocellular carcinoma. * Metastatic liver disease. * Other malignant liver tumors present at enrollment. * Clinical condition preventing routine surveillance follow-up. * Inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced liver fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection cirrhosis of liver fibrotic liver disease hepatitis B virus infection Liver Neoplasms metabolic dysfunction-associated steatotic liver disease hepatocellular carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced liver fibrosis Chronic hepatitis B Hepatocellular carcinoma Liver cirrhosis Metabolic dysfunction-associated steatotic liver disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.